Massillon, Ohio Clinical Trials
A listing of Massillon, Ohio clinical trials actively recruiting patient volunteers.
Found 32 clinical trials
Second Primary Lung Cancer Cohort Study (SPORT) (SPORT)
Patients who have had curative treatment for lung cancer are at an increased risk of developing second primary lung cancers (and other cancers) over the next 10 years. Doctors need to develop better ways of monitoring patients during follow up so we can intervene as quickly as possible with further …
- 0 views
- 12 Feb, 2026
- 1 location
- Online study
Prevalence of Subacromial Impingement Among Egyptian Swimmers : A Cross Sectional Survey Study.
In the available literature, there are no prevalence studies that show the incidence of subacromial impingement in swimmers in Egypt, this should be considered as it's one of the most commonly reported injuries worldwide in swimmers. There are also no available studies to show the difference in incidence of subacromial …
- 0 views
- 22 Sep, 2022
- 1 location
- Online study
Prevalence of Subacromial Impingement Among Egyptian Swimmers : A Cross Sectional Survey Study.
In the available literature, there are no prevalence studies that show the incidence of subacromial impingement in swimmers in Egypt, this should be considered as it's one of the most commonly reported injuries worldwide in swimmers. There are also no available studies to show the difference in incidence of subacromial …
- 0 views
- 22 Sep, 2022
- 1 location
- Online study
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary …
- 0 views
- 06 May, 2024
- +409 other locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma
This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …
- 0 views
- 16 Feb, 2024
- +7 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)
Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …
- 0 views
- 04 Dec, 2020
- +125 other locations
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
- 0 views
- 16 Feb, 2024
- +35 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …
- 0 views
- 04 Dec, 2020
- +12 other locations
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment.
- 0 views
- 16 Feb, 2024
- +4 other locations